Carbamazepine (Tegretol) — Competitive Intelligence Brief

Carbamazepine (Tegretol) (Carbamazepine (Tegretol)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant; sodium channel blocker. Area: Neurology.

marketed Anticonvulsant; sodium channel blocker Voltage-gated sodium channels Neurology Small molecule

Target snapshot

Carbamazepine (Tegretol) (Carbamazepine (Tegretol)) — Korean Epilepsy Society. Carbamazepine stabilizes neuronal membranes and reduces repetitive neuronal firing by blocking voltage-gated sodium channels.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Carbamazepine (Tegretol) TARGET	Carbamazepine (Tegretol)	Korean Epilepsy Society	marketed	Anticonvulsant; sodium channel blocker	Voltage-gated sodium channels
ketorolac + bupivacaine	ketorolac + bupivacaine	The Hospital for Sick Children	marketed	NSAID + local anesthetic combination	COX-1/COX-2 (ketorolac); voltage-gated sodium channels (bupivacaine)
Single Dose Liposomal Bupivicaine	Single Dose Liposomal Bupivicaine	University of California, Davis	marketed	Local anesthetic (liposomal formulation)	Voltage-gated sodium channels
Chloroprocaine Injection	Chloroprocaine Injection	Nova Scotia Health Authority	marketed	Local anesthetic (ester)	Voltage-gated sodium channels
Quetiapine and Topiramate	Quetiapine and Topiramate	University of Cincinnati	marketed	Atypical antipsychotic + anticonvulsant mood stabilizer combination	D2 dopamine receptor, 5-HT2A serotonin receptor (quetiapine); voltage-gated sodium channels, carbonic anhydrase (topiramate)
Lamotrigine (drug)	Lamotrigine (drug)	MaineHealth	marketed	Anticonvulsant / Antiepileptic drug	Voltage-gated sodium channels; glutamate release inhibition
Lamotrigine Generic "A"	Lamotrigine Generic "A"	University of Cincinnati	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant; sodium channel blocker class)

1. Korean Epilepsy Society · 1 drug in this class
2. Mario Negri Institute for Pharmacological Research · 1 drug in this class
3. Teva Pharmaceuticals USA · 1 drug in this class